Both Elekta Synergy and Agility offer advanced radiotherapy techniques that enable high precision treatment in managing a range of cancers. MOSAIQ creates an efficient clinical environment from diagnosis to treatment, giving clinicians more time to focus on patients.

NHS Supply Chain Capital Solutions managing director Andrew Brown noted that by purchasing a range of cancer treatment solutions from Elekta, the company expects to deliver high clinical value to several National Health Service (NHS) health care organizations and hospitals – as responsibly, cost-effectively and sustainably as possible.

"This deal with Elekta reflects our commitment to ensuring that patients receive the most efficient and latest treatment delivery techniques," Brown added.

Elekta Europe, Africa, Latin America and Middle East region executive vice president Ian Alexander said: "Getting the right treatment option for patients with cancer means better outcomes and fewer side effects. That’s why we have worked closely with the NHS for more than 20 years."

The deal was booked during Elekta’s fourth quarter of its fiscal year.